LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer
A Mandl,S Jasmine,TEG Krueger,R Kumar,IM Coleman,SL Dalrymple,L Antony,DM Rosen,Y Jing,B Hanratty,RA Patel,L Jin-Yih,J Dias,CA Celatka,AE Tapper,M Kleppe,M Kanayama,V Speranzini,YZ Wang,J Luo,E Corey,LA Sena,RA Casero Jr,T Lotan,BJ Trock,SK Kachhap,SR Denmeade,MA Carducci,A Mattevi,MC Haffner,PS Nelson,HY Rienhoff Jr.,JT Isaacs,WN Brennen
DOI: https://doi.org/10.1101/2024.01.17.576106
2024-01-22
Abstract:Lysine-specific demethylase 1 (LSD1 or ) has emerged as a critical mediator of tumor progression in metastatic castration-resistant prostate cancer (mCRPC). Among mCRPC subtypes, neuroendocrine prostate cancer (NEPC) is an exceptionally aggressive variant driven by lineage plasticity, an adaptive resistance mechanism to androgen receptor axis-targeted therapies. Our study shows that LSD1 expression is elevated in NEPC and associated with unfavorable clinical outcomes. Using genetic approaches, we validated the on-target effects of LSD1 inhibition across various models. We investigated the therapeutic potential of bomedemstat, an orally bioavailable, irreversible LSD1 inhibitor with low nanomolar potency. Our findings demonstrate potent antitumor activity against CRPC models, including tumor regressions in NEPC patient-derived xenografts. Mechanistically, our study uncovers that LSD1 inhibition suppresses the neuronal transcriptional program by downregulating ASCL1 through disrupting LSD1:INSM1 interactions and de-repressing YAP1 silencing. Our data support the clinical development of LSD1 inhibitors for treating CRPC – especially the aggressive NE phenotype.
Cancer Biology